Current evidence does not support routine use of combination therapy over monotherapy. Empirical combination therapy may be considered in carefully selected high-risk patients, with prompt de-escalation once susceptibilities are known.
Ayaz et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: